Larfors G, Andersson P, Jesson G, Liljebris C, et al. Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions. Eur J Haematol 2023 Jul 28. doi: 10.1111/ejh.14059.
PMID: 37503797